Rosetta Inpharmatics
|
“Looking back on how OVP enabled RSTA, I can now say they are among the best I have ever seen in terms of coherence and being attentive.” - Stephen Friend, CEO Rosetta Impharmatics was a digital biology company formed to develop technologies to improve drug discovery. OVP was there from day one, helping found the company out of the Hutchinson Cancer Center. Playing a central role in the formation of this company is a particular point of pride for OVP and a touch point in OVP's history in the space. Ultimately we took the company public and supported its acquisition by Merck in 2001. |
Rosetta Inpharmatics Acquired by Merck NYSE: MRK CEO: Stephen Friend |
